dc.contributor
Institut Català de la Salut
dc.contributor
[Ramlee S, Hulse D, Sala E, Aloj L] Department of Radiology, University of Cambridge, Cambridge, UK. [Bernatowicz K] Radiomics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Pérez-López R] Radiomics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei de Radiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Ramlee, Syafiq
dc.contributor.author
Hulse, David
dc.contributor.author
Pérez López, Raquel
dc.contributor.author
Sala, Evis
dc.contributor.author
Aloj, Luigi
dc.contributor.author
Bernatowicz, Kinga
dc.date.issued
2022-12-13T10:09:05Z
dc.date.issued
2022-12-13T10:09:05Z
dc.date.issued
2022-07-27
dc.identifier
Ramlee S, Hulse D, Bernatowicz K, Pérez-López R, Sala E, Aloj L, et al. Radiomic Signatures Associated with CD8+ Tumour-Infiltrating Lymphocytes: A Systematic Review and Quality Assessment Study. Cancers. 2022 Jul 27;14(15):3656.
dc.identifier
https://hdl.handle.net/11351/8660
dc.identifier
10.3390/cancers14153656
dc.identifier
000838972100001
dc.description.abstract
Cancer; Immune cells; Lymphocytes
dc.description.abstract
Cáncer; Células inmunes; Linfocitos
dc.description.abstract
Càncer; Cèl·lules immunitàries; Limfòcits
dc.description.abstract
The tumour immune microenvironment influences the efficacy of immune checkpoint inhibitors. Within this microenvironment are CD8-expressing tumour-infiltrating lymphocytes (CD8+ TILs), which are an important mediator and marker of anti-tumour response. In practice, the assessment of CD8+ TILs via tissue sampling involves logistical challenges. Radiomics, the high-throughput extraction of features from medical images, may offer a novel and non-invasive alternative. We performed a systematic review of the available literature reporting radiomic signatures associated with CD8+ TILs. We also aimed to evaluate the methodological quality of the identified studies using the Radiomics Quality Score (RQS) tool, and the risk of bias and applicability with the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool. Articles were searched from inception until 31 December 2021, in three electronic databases, and screened against eligibility criteria. Twenty-seven articles were included. A wide variety of cancers have been studied. The reported radiomic signatures were heterogeneous, with very limited reproducibility between studies of the same cancer group. The overall quality of studies was found to be less than desirable (mean RQS = 33.3%), indicating a need for technical maturation. Some potential avenues for further investigation are also discussed.
dc.description.abstract
This work was supported by the Cancer Research UK (CRUK) Cambridge Centre (CTRQQR-2021\100012) and the CRUK National Cancer Imaging Translational Accelerator (NCITA) (C22479/A28667); additional support was also provided by the National Institute for Health and Care Research (NIHR) Cambridge Biomedical Research Centre (BRC-1215-20014); the views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care; S.R. is supported by the Brunei “Sultan’s Scholar” scholarship from the Sultan Haji Hassanal Bolkiah Foundation; D.H. is supported by the Immune-Image: Specific Imaging of Immune Cell Dynamics Using Novel Tracer Strategies project (RG96994 and 831514); K.B. is supported by MSCA COFUND Beatriu de Pinós Grant (2019BP/00182); R.P.L. is supported by LaCaixa Foundation, a CRIS Foundation Talent Award (TALENT19-05), the FERO Foundation, the Instituto de Salud Carlos III-Investigacion en Salud (PI18/01395 and PI21/01019) and the Prostate Cancer Foundation (18YOUN19).
dc.format
application/pdf
dc.relation
Cancers;14(15)
dc.relation
https://doi.org/10.3390/cancers14153656
dc.relation
info:eu-repo/grantAgreement/ES/PE2013-2016/PI18%2F01395
dc.relation
info:eu-repo/grantAgreement/ES/PE2017-2020/PI21%2F01019
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Imatgeria per ressonància magnètica
dc.subject
Càncer - Tractament
dc.subject
DISEASES::Neoplasms
dc.subject
Other subheadings::Other subheadings::Other subheadings::/drug therapy
dc.subject
PHENOMENA AND PROCESSES::Cell Physiological Phenomena::Cellular Microenvironment::Tumor Microenvironment
dc.subject
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents::Antineoplastic Agents, Immunological
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Imaging::Tomography::Magnetic Resonance Imaging
dc.subject
ENFERMEDADES::neoplasias
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
dc.subject
FENÓMENOS Y PROCESOS::fenómenos fisiológicos celulares::microambiente celular::microambiente tumoral
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos::inmunoterapia antineoplásica
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::técnicas y procedimientos diagnósticos::diagnóstico por imagen::tomografía::imagen por resonancia magnética
dc.title
Radiomic Signatures Associated with CD8+ Tumour-Infiltrating Lymphocytes: A Systematic Review and Quality Assessment Study
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion